AU Patent

AU2017335839A1 — Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane

Assigned to Genentech Inc · Expires 2019-04-18 · 7y expired

What this patent protects

A combination therapy comprising a MEK inhibitor, a PD-1 or PD-L1 inhibitor, and a taxane is provided for the treatment of cancer, such as triple negative breast cancer.

USPTO Abstract

A combination therapy comprising a MEK inhibitor, a PD-1 or PD-L1 inhibitor, and a taxane is provided for the treatment of cancer, such as triple negative breast cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017335839A1
Jurisdiction
AU
Classification
—
Expires
2019-04-18
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.